Purpose Studies linking cholesterol levels to the development of colorectal neoplasia are inconsistent, and Mendelian randomization has been suggested as a way to help avoid problems with confounding and reverse causation. Methods We genotyped individuals who received a colonoscopy at Group Health (1998Health ( -2007 for 96 of 102 single-nucleotide polymorphisms identified by the Global Lipids Genetics Consortium. Participants included 139 advanced adenoma cases, 518 non-advanced adenoma cases, 380 non-adenomatous polyp cases, and 754 polypfree controls. All had at least one available pre-colonoscopy lipid measurement from electronic records maintained by Group Health.
Introduction
It is unclear whether dyslipidemia is a risk factor for colorectal neoplasia [1] [2] [3] [4] . It has been challenging for observational studies to determine if the co-occurrence of dyslipidemia and colorectal neoplasia is causal, given that both conditions share risk factors including high-fat diet, obesity, insulin resistance, smoking, and sedentary lifestyle [5, 6] . Mendelian randomization has been suggested as a potential solution [7] [8] [9] . Under assumptions employed in instrumental variable analysis [10] , Mendelian randomization studies use the distribution of alleles in the population to simulate randomized assignment to lower or higher cholesterol over the life course.
In the case of polygenic dyslipidemia, which is common and highly hereditable [11] , the Global Lipids Genetics Consortium (GLGC) genome-wide association study (GWAS) identified 102 germline single-nucleotide polymorphisms (SNPs) across 95 genes, reaching genome-wide statistical significance (p \ 5910 -8 ) for associations with blood concentrations of low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), triglycerides (TG), or total cholesterol (TC) [12] . Using these SNPs, we compared Mendelian randomization estimates with associations from clinical cholesterol measurements in a sample of men and women who underwent colonoscopy at Group Health, a large healthcare system in Washington State.
Materials and methods

Study population
Participants, aged 25-79, were enrollees of Group Health for at least 3 years who received a colonoscopy for any indication from 1998 to 2007. Eligibility criteria and participation information have been previously described [13] . All provided informed consent to access to medical records, completed a health history interview, and were asked to provide a DNA sample [14] . Study protocols were approved by the Institutional Review Boards of Group Health Research Institute and Fred Hutchinson Cancer Research Center.
Outcome ascertainment
Biopsies collected during colonoscopy received a standardized pathology review. Adenomas were distinguished from non-adenomatous polyps, which included hyperplastic polyps, traditional serrated adenomas, and sessile serrated adenomas. An advanced adenoma was defined as any tubular, tubulovillous, or villous adenoma C10 mm in diameter, with C20 % villous components, or high-grade dysplasia [15] . Participants were classified into four groups based on the lesion with the highest malignant potential: (1) advanced adenomas cases; (2) non-advanced adenoma cases; (3) non-adenomatous polyp cases; and (4) those without polyps (controls).
Phenotype measurement
All LDL, HDL, TG, and TC measurements from at most 20 years prior to the study colonoscopy were extracted from Group Health's database of laboratory results. We determined each participant's highest LDL, highest TG, highest TC measurement (zenith), and lowest HDL measurement (nadir). LDL or TG measurements were unavailable for about 30 % of participants, as these were not routinely used to assess cardiovascular disease risk at Group Health until the later period of data collection. Information on lipid-controlling drug prescriptions dispensed at eligible pharmacies was extracted from electronic pharmacy records [16] . Medication types included both statins and non-statins (fibric acid derivatives, cholesterol absorption inhibitors, and nicotinic acid).
Genotype measurement
Genotyping was performed using a custom GoldenGate assay from Illumina (San Diego, CA, USA). Prior to genotyping, 11 of the 102 SNPs identified by the GLGC were projected to have low likelihood of success based on Illumina's Assay Design Tool. For five of these SNPs (rs7515577, EVI5; rs1042034, APOB; rs9488822, FRK; rs12967135, MC4R; and rs7255436, ANGPTL4), we identified proxies with r 2 [ 0.3 from HapMap Caucasians. Six SNPs for which no proxy could be identified were excluded (rs1367117, APOB; rs13238203, TYW1B; rs4759375, SBNO1; rs2652834, LACTB; rs7241918, LIPG; and rs2277862, ERGIC3), leaving 96 of the 102 SNPs available for analyses. All SNPs were tested for departures from Hardy-Weinberg equilibrium.
Statistical analyses
For each of LDL, HDL, TG, and TC, we estimated three primary associations: (1) lipid-polyp odds ratios (OR) with 95 % confidence intervals (CI) comparing each case group with controls using polytomous logistic regression; (2) genotype-lipid associations using ordinary linear regression; and (3) genotype-polyp Mendelian randomization ORs using two-stage linear-logistic regression [17] . We used trait-specific allele scores created by counting alleles associated with an increased mean in the GLGC GWAS, weighted by effect size from their analysis (for HDL, the score was based on alleles associated with decreased mean HDL) [18] . For those missing genotypes, we imputed the mean score calculated among participants not missing genotypes. Minimally adjusted models included age at colonoscopy, sex, race, and year of colonoscopy. Fully adjusted models additionally included all variables listed in the footnote to Table 2 . Analyses restricted to only Caucasian study participants were also considered.
In secondary analyses, without using an allele score, we regressed genotype-lipid ORs on the association from the GLGC GWAS and tested for the statistical significance of slopes using inverse-variance-weighted linear regression [19] . To account for the possibility that only post-treatment cholesterol values may be available for some lipid-controlling drug users, we increased the zenith by 30 mg/dL for users with zenith LDL \ 130 mg/dL (n = 90). The GLGC considered a similar approach [12] . The value 130 mg/dL delineates borderline high LDL as defined by the Adult Treatment Panel III [5] , and a 30 mg/dL increase represents a conservative estimate of the average treatment effect of statins from randomized controlled trials [20] . We also considered excluding these n = 90 study participants and, separately, excluding all lipid-controlling drug users (n = 503).
Because we evaluated a single summary measure for each of four traits, we considered Bonferroni-corrected two-sided p values B0.05/4 = 0.0125 to denote statistical significance. Analyses were performed with SAS 9.2 (Cary, NC, USA) or R 3.0.0 (Vienna, Austria).
Results
Participant characteristics
A total of 2,506 participants completed the interview. DNA was unavailable from 640 participants, and 19 participants with DNA had an insufficient amount for genotyping. A further 56 had no cholesterol measurements available from the Group Health database of laboratory measurements. No differences were noted in the distribution of excluded participants by case-control status. Most were Caucasian, and most identified to have polyps were men (Table 1) .
Lipid-polyp associations
Increases in zenith LDL, zenith TG, and zenith TC were each associated with increased odds of advanced adenomas (Table 2) . Associations for zenith LDL were similar in analyses involving the substituted treatment effect, excluding participants for whom we substituted a treatment effect, and also excluding all of those without record of lipid-controlling drug prescriptions (not shown).
Genotyping results
All but three genotyped SNPs were missing for \1 % of participants. Exceptions were rs2068888 (CYP26A1) missing for 74 % of participants, and rs7134375 (PDE3A) and rs4420638 (APOE/APOC1) both missing for 26 % of participants due to clustering failures. For all but one SNP, rs4129767 (PGS1), the minor allele observed among our controls matched the minor allele reported from the GLGC GWAS. To be consistent with the GLGC GWAS, we report associations for the G allele of rs4129767 (frequency of 54 % in controls, but was 49 % in the GLGC GWAS).
Genotype-lipid associations
Genotype-lipid associations using GLGC-weighted allele scores were in the expected direction and highly statistically significant among our 754 controls, with p values ranging from 1 9 10 -6 for the regression of LDL allele score on zenith LDL to 1 9 10 -17 for the regression of HDL allele score on nadir HDL (Table 3) . A variant of CETP (rs3764261) met genome-wide statistical significance for the association with nadir HDL among controls. Allele scores were not associated with any of the covariates included as adjustment variables (not shown).
Genotype-polyp associations
None of the Mendelian randomization estimates for genotype-polyp associations based on allele scores was statistically significant (Table 4 ). The genotype-lipid association appeared linear based on deciles in controls (Fig. 1) . Multi-SNP analyses without using allele scores also revealed no statistically significant associations. In general, polymorphisms with the largest magnitude per allele associations with lipid phenotypes, either in the GLGC GWAS or in our controls, were not associated with colorectal polyps (Supplemental Figures 1 and 2) . Results for analyses restricted to only Caucasian study participants were similar (not shown).
Discussion
We found that higher extremes in LDL, TG, and TC occurring, on average about 4-6 years before colonoscopy depending on the trait, were associated with the prevalence of advanced adenomas. In contrast, evidence from GWASidentified allele scores was not strong, particularly in light of the apparent inconsistency between which SNPs were associated with lipid phenotypes and which were associated with polyps. Until larger studies can be conducted, this
analysis provides a preliminary indication that genetically influenced cholesterol levels may be unrelated to the development of colorectal neoplasms.
Mendelian randomization analyses require strong assumptions that are not readily verifiable. Alleles must function to alter blood lipid levels without unmeasured common causes of both the polymorphism and polyp occurrence, and without the alleles being involved in mechanisms that influence polyp formation separate from the mechanisms by which they alter cholesterol levels (i.e., no genetic pleiotropy) [10] . Mendelian randomization analyses of traits with complex biology can be difficult to interpret. Some SNPs we evaluated may be inappropriate for use as instrumental variables due to pleiotropy or weak instrument bias [21] . It has been suggested that, given the strong assumptions involved, null Mendelian randomization results may be more plausible than positive results [22] . We acknowledge that the modest sample size is a primary limitation [23, 24] . It is estimated that the 102 SNPs from the GLGC GWAS collectively explain approximately 12 % of total variation, or about 30 % of the expected genetic variation, in each lipid trait [12] . For comparison, in this same sample, an allele score comprised of 13 SNPs identified from GWAS of colorectal cancer was associated with increased prevalence of advanced adenomas with p = 2910 -3 [14] , despite evidence that these SNPs explain far less of the heritability of colorectal cancer than the GLGC GWAS SNPs explain of the heritability of lipids [25] . Larger studies will benefit from enhanced statistical power, but the ability of such studies to harmonize pathology information, past lipid trajectories, and pharmacy data will likely be limited. Larger studies should also attempt to include additional polymorphisms from more powerful genetic association studies of lipid traits that explain more of the expected genetic variation, as cholesterol loci of potential relevance to colorectal neoplasia may not be fully represented among these 102 SNPs.
The ability to compare estimates from Mendelian randomization with those from clinical lipid measurements was a key motivation for collecting data on both genotype and phenotype. This also permitted an internal assessment of the strength of the instruments. Genes in cholesterol metabolism pathways have not been among the loci reaching genome-wide statistical significance from GWAS of colorectal polyps [26, 27] or invasive colorectal cancer [28, 29] . Thus, we used trait-specific allele scores in an attempt to operationalize sufficiently strong instruments. Because use of such scores has limitations [18] , we chose to supplement multi-SNP analyses with single-SNP analyses.
It is not typically necessary to adjust for disease risk factors in genetic association studies, and the minimally adjusted estimates we report align closely with the classical notions of Mendelian randomization. In order to enhance instrument purity, we could have eliminated lipid SNPs representative of loci found to be also associated with other risk factors for colorectal polyps. Having found no clear overall signal of association with all SNPs in a score and no clear pattern of association in single-SNP analyses, retrospective pruning of the SNP list based on external information on genotypic associations with other phenotypes did not prove to be useful in identifying associations with polyps. Lastly, we acknowledge that race adjustment alone may be insufficient to adequately control for population stratification [30] , but ancestry- CI confidence interval, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, OR odds ratio, TC total cholesterol, TG triglycerides a OR is adjusted for age at colonoscopy, sex, race, and data-collection period informative markers were not available in this sample, and the results changed little when those not of Caucasian race were excluded. In summary, despite observing a statistically significant positive association between higher pre-colonoscopy extremes in LDL, TG, and TC and the prevalence of advanced adenomas, there was insufficient evidence to conclude that genetic variation controlling cholesterol levels may be involved in polyp formation. On one hand, the magnitude of the point estimates for the Mendelian randomization odds ratios, particularly for the association between advanced adenomas and SNPs for LDL and TG, were of comparable magnitude with those for measured zenith LDL and zenith TG. On the other hand, Mendelian randomization odds ratios did not achieve statistical significance, and SNPs known to have the largest magnitude association with blood lipids were not associated with the prevalence of polyps.
If confirmed in larger studies, a null association from Mendelian randomization analysis may suggest that clinical dyslipidemia is only a bystander to environmental or genetic causes of neoplastic growth in the colon and rectum. Dyslipidemia may be a marker of, for instance, the type of visceral adiposity, insulin resistance, or dietary exposures that, independent of biological pathways that involve cholesterol metabolism, could lead to polyp formation. Alternatively, larger studies may have the power to identify genetic associations that link extremes in blood cholesterol to neoplasia, consistent with the magnitude of some of our point estimates, should they be replicated with increased precision. 
